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Background:TCR recognition of bipartite ligands composed of self (MHC) and non-self (peptide) maintains T-cell specificity.
Results:Mutation of residues in the cognate peptide override TCR mutations that enhance MHC binding.
Conclusion: TCR-pMHC binding affinity requires specific TCR-peptide interactions.
Significance: Stabilization of TCR-pMHC engagement by TCR-peptide interactions maintains T-cell specificity and prevents
recognition of self-pMHC in the periphery.
 T-cell receptors (TCRs) engage antigens using comple-
mentarity-determining region (CDR) loops that are either germ
line-encoded (CDR1 and CDR2) or somatically rearranged
(CDR3). TCR ligands compose a presentationplatform (major his-
tocompatibility complex (MHC)) and a variable antigenic compo-
nentconsistingofa short “foreign”peptide.Thesequenceofevents
when the TCR engages its peptide-MHC (pMHC) ligand remains
unclear. Some studies suggest that the germ line elements of the
TCR engage the MHC prior to peptide scanning, but this order
of binding is difficult to reconcile with some TCR-pMHC struc-
tures.Here,weusedTCRs that exhibited enhancedpMHCbind-
ing as a result of mutations in either CDR2 and/or CDR3 loops,
that bound to the MHC or peptide, respectively, to dissect the
roles of these loops in stabilizing TCR-pMHC interactions. Our
data show that TCR-peptide interactions play a strongly domi-
nant energetic role providing a binding mode that is both tem-
porally and energetically complementary with a system requir-
ing positive selection by self-pMHC in the thymus and rapid
recognition of non-self-pMHC in the periphery.
 T-cells protect against pathogens and cellular malignan-
cies by recognizing short peptide fragments bound to major
histocompatibility complex (pMHC)4molecules (1, 2). The rig-
ors of T-cell immunity require that TCRs bind to self-pMHC
during thymic selection but discriminate between self and non-
self-pMHC thereafter by the rapid scanning of huge numbers of
potential antigens on the target cell surface (3, 4). Here, we
examine how TCR interactions with the variable peptide com-
ponent of the antigen are balanced against contacts with the
MHC to enable T-cells to activate if sensing danger, while
remaining tolerant to self.
X-ray crystallographic studies have shown that the  TCR
docks diagonally across the pMHC class I (pMHCI) peptide
binding groove with the TCR  chain contacting the MHCI 2
helix and the TCR  chain contacting theMHCI 1 helix (5). A
similar diagonal binding modality has been observed for TCR-
pMHC class II interactions with the TCR  chain contacting
theMHCII 1 helix and the TCR  chain contacting theMHCI
1 helix. This fixed polarity is conserved in all published TCR-
pMHCI structures to date, although the binding angle and con-
tacts between individual TCR-pMHCI complexes can vary sub-
stantially (5). TCR recognition of pMHC is mediated through
the TCR complementarity-determining region (CDR) loops.
Although not the case with all TCR-pMHC pairs (6), the cur-
rent dogma proposes that the germ line-encoded TCR CDR2
loops contact mainly the conserved helical region of the MHC
surface (TCR-MHC self-interaction); the somatically rearranged,
hypervariable CDR3 loops contact mainly the antigenic peptide
(TCR-peptide non-self interaction), and the CDR1 loops lie in
between, contacting both the peptide and theMHC (5).
This binding conformation has led to the suggestion that
TCRs contact MHC in a genetically conserved manner (7–10).
Indeed, a study by Wu et al. (11) investigating the role of the
TCR CDR loops during pMHC binding concluded that an ini-
tial transition state is formed between the TCR and the MHC
surface enabling the TCR to scan the antigenic peptide (two-
step binding) (12). This two-step binding model is considered
to represent an important mechanism of allowing T-cells to
sample a diverse array of pMHC antigens (3, 4, 13). In support
* This work was funded by Royal Society Grant RG080077, Wellcome Trust
Program Grant WT086716MA, and Biotechnology and Biological Sciences
Research Council Grant BB/H001085/1.
Author’s Choice—Final version full access.
The atomic coordinates and structure factors (code 4MNQ) have been deposited
in the Protein Data Bank (http://wwpdb.org/).
1 Wellcome Trust Research Career Development Fellow supported by
Grant WT095767. To whom correspondence may be addressed. Tel.:
442920687006; E-mail: coledk@cf.ac.uk.
2 Supported by a Tenovus Ph.D. studentship.
3 To whom correspondence may be addressed. Tel.: 442920687055; E-mail:
sewellak@cf.ac.uk.
4 The abbreviations used are: pMHC, peptide-major histocompatibility complex;
SPR, surface plasmon resonance; TCR, T-cell receptor; CDR loop, complemen-
tarity-determining region loop; PDB, Protein Data Bank;MHCI, pMHC class I.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 2, pp. 628–638, January 10, 2014
Author’s Choice © 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
628 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 2•JANUARY 10, 2014
 at U
N
IV
 W
A
LES CO
LL O
F CA
RD
IF on June 26, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of this notion, combined studies have suggested the existence of
so-called “interaction codons” that enable the TCR to contact
the MHC surface in a conserved manner (7–10). Furthermore,
structural comparison of different TCRswith genetically identical
CDR2 loops, in complex with the same pMHC, lends support to
the idea that some TCRsmay use genetically fixed pairwise inter-
actions to bind to theMHC surface (9, 14). In combination, these
datapredict that interactionsbetween theTCRandMHCstabilize
the initial “encounter complex.” However, there is also a body of
evidence that contradicts this model of TCR binding (15–21).
Thus, there is still much controversy over this central question
concerning the nature of T-cell antigen recognition.
The binding affinity of natural TCR-pMHC interactions
(KD 0.1–500 M) (22, 23) is near the limits of detection using
current biophysical techniques. This restricts the scope for
investigating TCR-pMHC interactions by mutating important
contacts, because altering this weak interaction often results in
the loss of any detectable binding using surface plasmon reso-
nance (SPR). To examine the roles of the TCRCDR loops when
binding to pMHC, we designed a range of enhanced affinity
soluble TCRs with mutations in either their CDR2 and/or
CDR3 loops. These unique enhanced affinity reagents enabled
investigation of the effects of altering specific interactions
between the TCR and MHC or TCR and peptide to examine
how individual components of the interface between the TCR
and pMHCI contribute to T-cell antigen recognition. These
data shed new light on how T-cells might be selected in the
thymus to maintain tolerance to self, the mechanism of T-cell
cross-reactivity, and the nature of T-cell antigen recognition.
EXPERIMENTAL PROCEDURES
Generation of Expression Plasmids—Anumber of constructs
were prepared that contained wild type and high affinity TCRs
to the HLA A*0201-restricted antigens, Melan-A/MART-
1(26–35) ELAGIGILTV (24) and hTERT(540–548) ILAKFL-
HWL (25). TheHLAA*0201-ELAGIGILTV- andHLAA*0201-
ILAKFLHWL-specific wild type TCRs (MEL5 and ILA1 TCRs,
respectively), the high affinity TCR  and  chains, HLA
A*0201 heavy chain, and 2m were generated by PCR
mutagenesis (Stratagene) and PCR cloning. All sequences were
confirmed by automated DNA sequencing (Lark Technolo-
gies). The high affinity HLA A*0201-ELAGIGILTV and HLA
A*0201-ILAKFLHWL TCRs were produced using a phage dis-
play library as reported previously (26). All of the TCR
sequences were constructed implementing a disulfide-linked
construct to produce the soluble domains (variable and con-
stant) for both the  (residues 1–207) and  chains (residues
1–247) (27, 28). TheHLAA2 heavy chain (residues 1–248) (1,
2, and 3 domains), tagged with a biotinylation sequence, and
2m (residues 1–100) were also cloned and used to make the
pMHCI complexes. The TCR  and  chains, the HLA A2 
chain and 2m sequences were inserted into separate pGMT7
expression plasmids under the control of the T7 promoter (27).
Protein Expression, Refolding, and Purification—Competent
Rosetta DE3 Escherichia coli cells were used to produce the
TCR  and  chains, HLA A*0201 heavy chain and 2m in the
form of inclusion bodies using 0.5 mM isopropyl 1-thio--D-
galactopyranoside to induce expression as described previously
(27, 29, 30).
pMHCI Biotinylation—Biotinylated pMHCIwas prepared as
described previously (31).
SPR Equilibrium Analysis—The binding analysis was per-
formed using a BIAcore T100TM equipped with a CM5 sensor
chip as reported previously (32).
SPR Kinetic Analysis—Experiments were carried out to
determine the Kon and Koff values for the TCRs at 25 °C as
reported previously (33). Briefly, for all kinetic experiments,
300 response units of pMHCwere coupled to theCM5 sensor
chip surface. The TCR was then injected at concentrations
ranging from 10 times above and 10 times below the known KD
value of the interaction at 45 l/min. The Kon and Koff values
were calculated assuming 1:1 Langmuir binding (AB 
BABmax/(KDB)), and the datawere analyzed using a global fit
algorithm (BIAevaluationTM 3.1).
SPR Kinetic Titration Analysis—To stringently examine the
binding of the TCRs at a greater range of concentrations, we
used a newmethod for analyzing the kinetic parameters of high
affinity interactions with long off rates (34). Each TCRwas ana-
lyzed at five concentrations that represented the greatest range
we could accurately achieve around the KD value of each inter-
action.During the analysis,300 response units of pMHCwere
immobilized onto the CM5 sensor chip surface. Each concen-
tration of TCR was injected at a high flow rate of 45 l/min for
a 240-s association period and a 120-s dissociation period. The
final andhighest concentration had a longer dissociation period
of 600 s. A fast flow rate and a low amount of immobilized
pMHC were used to limit association and dissociation mass
transfer limitations as recommended by the experts at BIA-
coreTM. The Kon and Koff values were calculated assuming 1:1
Langmuir binding (ABBABmax/(KDB)), and the data were
analyzed using the kinetic titration analysis algorithm (BIAe-
valuationTM Version 3.1) (35).
Crystallization and X-ray Data Collection—11-A2-ILA
crystals were grown in 20 mM Tris, pH 7.5, 20% PEG 4000, and
10 mM NaCl. All crystals were soaked in 30% ethylene glycol
before cryo-cooling. Data were collected at 100 K at the Dia-
mond Light Source, UK. Reflection intensities were estimated
with the XIA2 package (36), and the data were scaled, reduced,
and analyzed with SCALA and the CCP4 package (37). Struc-
tures were solved with molecular replacement using PHASER
(38). Sequences were adjustedwithCOOT (39), and themodels
were refined with REFMAC5. Graphical representations were
preparedwith PyMOL (40). The reflection data and finalmodel
coordinates were deposited with the PDB database (11-A2-
ILA, PDB 4MNQ).
RESULTS
Design of a Panel of High Affinity TCRs Specific for Two Dif-
ferent HLA A*0201-restricted Peptides—Investigating the indi-
vidual roles of the TCR CDR loops when binding to pMHC has
been difficult because the weak binding affinities of natural
TCR-pMHC interactions (0.1–500 M) (22, 23) are close to the
limits of detection by SPR. To overcome this problem, we
designed a range of soluble TCRs with up to 18,500-fold
enhancement in affinity for cognate antigen using CDR loop
TCR-Peptide Specificity Governs Antigen Recognition
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mutations selected by phage display (Table 1) (26). We first
measured the binding affinity and kinetics of wild type and
enhanced affinity TCRs specific for either the HLA A*0201-
restricted peptide antigens, Melan-A/MART-1(26–35)
(ELAGIGILTV), or hTERT(540–548) (ILAKFLHWL). The
HLA A*0201-ELAGIGILTV-specific TCRs with mutated
CDR2 or CDR2 and CDR3 loops bound with considerably
stronger affinities (KDs between 12 and 897 times greater) than
the parentwild typeTCR (MEL5) (Fig. 1 andTable 2). TheHLA
A*0201-ILAKFLHWL specific TCRswithmutatedCDR2 loops
bound to cognate antigen with a substantially stronger affinity
(KD values between 1423 and 4066 times greater) compared
with the parent wild type TCR (ILA1) (Fig. 2 and Table 3).
Similarly, when the mutated CDR2 and CDR3 loop mutations
were combined, we observed a further increase in binding affin-
ity (KD values up to 18,500 times greater than ILA1 TCR), indi-
cating that the mutations could be used cooperatively (Fig. 3
and Table 3). In agreement with our previous findings (26, 34,
41–44), enhanced TCR affinity was due to small increases in
the on-rate, and vastly extended off-rates (Tables 2 and 3, Figs.
1–3). The stronger affinities of the high affinity TCRs
enabled the modulation of individual components of the
TCR-peptide interaction through peptide mutations while
maintaining enough residual binding to detect using SPR in
later experiments.
High Affinity CDR2 Loop Mutated TCRs Do Not Bind to
“Null” Peptides—Our recent structure of a high affinity variant
of the MEL5 TCR (34) demonstrated that the mutated CDR2
region of the high affinity MEL5-derived TCRs used in this
study was in an identical position to the wild type MEL5 TCR
(24), distal from the peptide (Fig. 4, A and B). Thus, we con-
cluded that mutations at residues in the peptide were very
unlikely to directly affect the high affinity interactions between
theMEL5 derived high affinity TCRs and theMHC surface.We
reasoned that, because the general dogma of TCR engagement
postulates that TCR-MHC interactions bind before TCR-pep-
tide sampling, the high affinity interaction between the MEL5-
derived TCRs and the MHC surface should retain some mea-
surable ability to bind to the surface ofHLAA2 irrespectively of
the bound peptide, because the interaction between the TCR
and the peptide should only account for a small proportion of
the overall binding energy (G). To investigate the role of pep-
FIGURE 1.Affinity and kinetic analysis ofwild type and high affinityMEL5-derived TCRs. A–I, these datawere produced using a BIAcore T100TM andwere
then analyzed using equilibrium analysis, kinetic global fit analysis, and kinetic titration analysis. The raw data and the fits are shown in each panel. These data
illustrate the improved binding capabilities of the high affinity mutant HLA A2-ELAGIGILTV-specific TCRs compared with the MEL5 TCR. None of the HLA
A2-ELAGIGILTV-specific TCRs bound to the HLA A2-ELAGIGILTV with alanine or glycine substitutions.
TABLE 1
Sequence comparison of high affinity TCRs
TCR-Peptide Specificity Governs Antigen Recognition
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tide modifications on TCR-pMHC docking, we manufactured
two null HLA A*0201-nonamer peptide complexes where
nonprimaryMHC anchors were substituted with either glycine
or alanine. However, we were unable to detect binding of any of
the HLA A*0201-ELAGIGILTV- or HLA A*0201-ILAKFL-
HWL-specific high affinity TCRs tested against the HLA
A*0201-GLGGGGGGV or HLA A*0201-ALAAAAAAV null
antigens (Tables 2 and 3). These observations are remarkable
when considering that, for example, the CDR2 loop modified
ILA12 TCR bound to HLA A*0201-ILAKFLHWL with an
affinity 4000 times greater than the wild type ILA1 TCR
(Table 3 and Fig. 2). These data support the notion that specific
interactions between theTCR and peptide are required to allow
the TCR to effectively engage MHC and demonstrate that
changes to the antigenic peptide overridemutations in theTCR
that enhance contacts with the MHC molecule.
CDR2-mutated High Affinity HLA A*0201-ELAGIGILTV-
specific TCRs Are Extraordinarily Sensitive to Peptide Sub-
stitutions—To investigate the role of more conservative
peptide modifications on TCR binding affinity, we intro-
duced single alanine substitutions into the HLA A*0201-
ELAGIGILTV (MART-1/Melan A-derived) peptide antigen.
We substituted residues in the peptide that were very
unlikely to directly affect the high affinity regions of the
MEL5-derived high affinity TCRs and the MHC surface,
according to our structural evidence (Fig. 4, A and B) (24, 34).
This enabled the determination of the effect of altering TCR-
peptide contacts on TCR-MHC binding. Neither the MEL5
TCR nor any of the high affinity TCRs retained the ability to
bind to HLA A*0201-ELAAIGILTV, HLA A*0201-ELAGI-
AILTV, HLA A*0201-ELAGIGALTV, or HLA A*0201-ELA-
GIGILAV (Table 2). This observation that single alanine sub-
stitutions in the native peptide can completely abrogate
binding of all of the high affinity HLAA*0201-ELAGIGILTV-
specific TCRs reaffirms the notion that specific interactions
between the TCR and peptide are required in order for optimal
docking with the MHC surface to occur, and this is consistent
with our previous findings using this system (34).
FIGURE 2.Affinity andkinetic analysis ofwild type andhigh affinity ILA1-
derived TCRs. A–C, these data were produced using a BIAcore T100TM and
were then analyzed using equilibrium analysis, kinetic global fit analysis, and
kinetic titration analysis. The raw data and the fits are shown in each panel.
These data show that the ILA11 and ILA12 TCRs bound to HLA A*0201-
ILAKFLHWL with4000 times greater affinity than the wild type ILA1 TCR.
TABLE 2
Kinetic and affinity analysis of high affinity HLA-A*0201-ELAGIGILTV-
specific TCR binding to alanine- and glycine-substituted peptides
TABLE 3
Kinetic and affinity analysis of high affinity HLA-A*0201-ILAKFLHWL-
specific TCRs binding to alanine- and glycine-substituted peptides
* G0 G0 of each TCR binding to HLA A2-ILAKFLHWL alanine variants
minus G0 of TCR to HLA A2-ILAKFLHWL.
TCR-Peptide Specificity Governs Antigen Recognition
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Affinity-enhanced CDR2 Loops of the ILA1-derived TCRs
Do Not Contact Alanine-substituted Peptide Residues—Previ-
ous structural comparisons of wild type and high affinity TCRs
(34, 41–43) show that these molecules adopt a near identical
binding mode (Fig. 5). To confirm that alanine substitutions of
these peptide residues would not directly impinge on the
mutated residues in the high affinity CDR2 loops of the ILA1-
derived TCRs, we solved the structure of the ILA111 TCR in
complex with HLA A*0201-ILAKFLHWL. The complex was
solved to a resolution of 2.4 Å in space group C121. The reso-
lution was sufficiently high to show that the interface between
the twomolecules was well ordered and contained well defined
electron density. The crystallographic R/Rfree factors were 20.1
and 24.6%, within the accepted limits shown in the theoretically
expected distribution (Table 4) (45). The structure demon-
strated that the mutated CDR2 region of the high affinity
11 TCR could not directly contact the mutated residues in
the peptide (Fig. 4, C and D, and Table 5).
HLA A*0201-ILAKFLHWL Peptide Substitutions Dispropor-
tionately Affect the Binding of High Affinity CDR2 Loop
Mutated TCRs—We then measured the binding of the HLA
A*0201-ILAKFLHWL-specific wild type ILA1 TCR and high
affinity derivative TCRs to HLA A*0201-ILAAFLHWL and
HLA A*0201-ILAKFAHWL (Table 3 and Fig. 3). The ILA11
high affinity TCR bound to HLA A*0201-ILAAFLHWL and
HLA A*0201-ILAKFAHWL with 100 and 200 times weaker
affinity, respectively, than to HLA A*0201-ILAKFLHWL. This
difference corresponded to a G value (difference in binding
energy, G, between the ILA11 high affinity TCR interacting with
HLA A*0201-ILAKFLHWL versus HLA A*0201-ILAAFLHWL
and HLA A*0201-ILAKFAHWL) of 2.54 and 2.94 kcal/
mol1, respectively. We then repeated this analysis using the
FIGURE 3. Effect of alanine peptide substitutions on high affinity ILA1-derived TCR binding. Binding affinity and kinetic analysis of the HLA A*0201-
ILAKFLHWL-specific high affinity ILA11, ILA111, and ILA112 TCRs toHLAA2-ILAKFLHWL, HLAA2-ILAAFLHWL, andHLAA2-ILAKFAHWL (A–I). These data
were producedusing a BIAcore T100TM andwere then analyzedusing equilibriumanalysis, kinetic global fit analysis, and kinetic titration analysis. The rawdata
and the fits are shown in each panel. These data show the effect of the HLA A2-ILAAFLHWL and HLA A2-ILAKALHWL peptide modifications on the binding of
the high affinity TCRs compared with HLA A2-ILAKFLHWL. These support the notion that TCR-peptide interactions govern TCR-pMHC binding because,
although the ILA111 TCRwith amutated CDR2 loop did not contact the peptide, the difference in binding between the ILA11 TCR and the ILA111 TCR
to HLA A2-ILAAFLHWL and HLA A2-ILAKALHWL compared with HLA A2-ILAKFLHWL is disproportionately different.
FIGURE 4. Peptidemodifications do not directly impinge on the binding of
mutated high affinity TCR residues. The complex structures of high affinity
MEL5- and ILA1-derived TCRs show that peptide modifications do not directly
impingeon thebindingofmutatedhighaffinity TCR residues.A,wild typeMEL5-
A2-ELA (PDB code 3HG1 (24)) complex structure showing the MHC in gray sur-
face, themutated peptide residues in yellow stick and surface (nonmutated resi-
dues in green), and the positions of the TCR CDR2 loops in orange sticks and
surface. B, high affinity 2417-A2-ELA (PDB code 4JFF (34)) complex structure
(2417 is a high affinity version of the MEL5 TCR) showing the MHC in gray
surface, the mutated peptide residues in yellow stick and surface (nonmutated
residues in green), and the positions of the TCR CDR2 loops in orange sticks and
surface. In this structure, the high affinity mutations in the TCR CDR2 loop are
colored blue and are distal from the peptide. C, high affinity 11-A2-ILA (PDB
code 4MNQ) complex structure (11 is a high affinity version of the ILA1 TCR)
showingtheMHCingraysurface, themutatedpeptideresidues inyellowstickand
surface (nonmutated residues in red), and thepositions of the TCRCDR2 loops in
orange sticks and surface.D, specific contacts between the high affinitymutated
residues in the11 TCR CDR2 loop (blue sticks), theMHC (gray sticks), and the
peptide (red). The peptide residues that were mutated to alanine (yellow) were
not directly contacted by the high affinity mutated residues in the 11 TCR
CDR2 loop. Overall, these structures demonstrate that TCR residues that have
been mutated in the CDR2 loops of high affinity TCRs do not directly contact
residues that weremutated to alanine in the peptide.
TCR-Peptide Specificity Governs Antigen Recognition
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ILA111 and ILA112 TCRs. These TCRs contained mod-
ified CDR2 loops but identical CDR3 loops to the ILA11 TCR.
According to the assumption that TCR-MHC interactions pre-
cede TCR-peptide interactions, we reasoned that each of these
TCRs should retain their individual TCR-MHC contacts
because only the TCR-peptide interaction should be directly
affected (as in Fig. 6A). Therefore, the difference in binding
affinity observed for the ILA11 TCR between HLA A*0201-
ILAKFLHWL compared with HLA A*0201-ILAAFLHWL and
HLAA*0201-ILAKFAHWL (100 and 200 timesweaker affinity,
respectively) should be similar to the ILA111 and ILA112
TCRs. However, the ILA111 TCR bound to the HLA
A*0201-ILAAFLHWL and HLA A*0201-ILAKFAHWL with
4150 and 1100 times weaker affinity (G value of 4.6 and 3.87
kcal/mol1), respectively (Table 3 and Figs. 3 and 6B). The
ILA112TCRbound toHLAA*0201-ILAAFLHWLandHLA
A*0201-ILAKFAHWL with 2710 and 1065 times weaker
affinity (G value of 4.37 and 3.85 kcal/mol1), respec-
tively (Table 3 and Fig. 3). These data demonstrate that TCR
interactions with the peptide and MHC are strongly coupled
and that modifying the TCR-peptide interaction has a dis-
proportionately strong detrimental energetic effect on TCR-
MHC binding.
Effect of Peptide Substitutions on the Binding Kinetics of High
Affinity CDR2 Loop Mutated TCRs—Kinetic binding analyses
were carried out at 25 °C to measure the on-rate (Kon) and off-
rate (Koff) for each TCR-pMHCI interaction (Figs. 1–3 and
Tables 2 and 3). These analyses were important to reveal the
kinetic basis for the effect of altering the TCR-peptide interac-
tions by modifying the antigenic peptide. Interestingly,
although alanine mutations within the central peptide residues
reduced the binding affinity of all of the high affinity TCRs
tested to a different extent (97–4150-fold reduction in binding
affinity), the on-rate was not substantially affected (average
decrease of 10 times) (Tables 2 and 3). Conversely, the stability
of the TCR-pMHC complex was affected by a greater extent, as
evident by the faster off-rate observed (average increase of 200
times) (Tables 2 and 3). Therefore, a faster off-rate was the
major kinetic determinant governing the decrease in binding
affinity between the high affinity CDR loop mutated TCRs and
the alanine-substituted peptide ligands. These data suggest that
in order for the TCR to form a stable long lived interaction with
cognate pMHC, the TCRmust be able to bind to the peptide to
allow optimal MHC docking. Thus, in the systems we have
studied, successful TCR-peptide sampling must precede (or
occur at the same time as) the stabilizing interaction between
the TCR and the MHC surface.
DISCUSSION
Antigen recognition by the TCR usually involves contacts
with both self (MHC) and non-self (the antigenic peptide) (5,
16). To avoid autoreactivity, the self-interaction between the
TCR and MHC must not be sufficient to activate peripheral
T-cells independently of the non-self TCR-peptide interaction.
The current database of TCR-pMHC complex structures
FIGURE 5. Conformation of TCR CDR loops remains very similar between
modified high affinity TCRs and their wild type progenitors. Comparison
of the CDR loop positions of previously published high affinity and wild type
TCRs. A, wild type MEL5-A2-ELA complex (24) (CDR loops in orange ribbon)
and the high affinity 2417-A2-ELA complex (34) (CDR loops in green rib-
bon). B, wild type A6-A2-LLF complex (27) (CDR loops in orange ribbon) and
the high affinity c134-A2-LLF complex (41) (CDR loops in green ribbon).C,wild
type 1G4-A2-SLL complex (64) (CDR loops in orange ribbon) and the high
affinity c58c62-A2-SLL (CDR loops in green ribbon), c49c50-A2-SLL (CDR loops
in blue ribbon), c549c61-A2-SLL (CDR loops in yellow ribbon), and c5c1-A2-SLL
(CDR loops in cyan ribbon) complexes (42, 43). In all cases, the relative posi-
tions of the CDR loops over the pMHC for the wild type TCRs and their high
affinity TCR derivative are virtually identical.
TABLE 4
Datacollectionandrefinementstatistics for11-A2-ILAcomplexstructure
One crystal was used for solving the structure. Values in parentheses are for the
highest resolution shell.
11-A2-ILA
PDB code 4MNQ
Data collection
Space group P3221
Cell dimensions
a, b, c 97.14, 97.14, 123.08 Å
, ,  90, 90, 120°
Resolution (Å) 49.7 to 2.4 Å (10.7 to 2.4 Å)
Rmerge 19.2%
I/I 16.6
Completeness 100%
Redundancy 10.9
Refinement
Resolution 2.4 Å
No. of reflections 25,403
Rwork/Rfree 20.1/24.6
No. of atoms 3694
Protein 3492
Ligand/ion 41
Water 161
B-factors 44.63
Protein 44.60
Ligand/ion 60.79
Water 41.10
Root mean square deviations
Bond lengths 0.022 Å
Bond angles 1.206°
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TABLE 5
11-A2-ILA contacts (residues mutated fromwild type shown in red)
* A 3.4-Å cutoff was used for H-bonds and salt bridges, and a 4-Å cutoff was used for van der Waals (vdW).
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shows that the interaction between TCR and antigenic peptide
can play a minimal structural role, often being responsible for
less than a third of the binding interface relative to contacts
between the TCR and MHC (5). Thus, the molecular mecha-
nism by which the TCRmaintains peptide-specific recognition
is not immediately obvious.
To re-examine how theTCRCDR loops co-operatively act to
stabilize TCR-pMHC binding, we designed a range of soluble
TCRs that exhibited up to a 18,500-fold enhancement in affin-
ity for cognate antigen using CDR loop mutations selected by
phage display (26). Previous studies using high affinity TCRs
have shown that these artificial reagents retain a high level of
antigen specificity similar to their wild type progenitors (34,
46–48). In all cases, the enhanced affinity observed for the
mutated TCRs compared with the wild type TCRs was due to
small differences in the on-rate but a vastly extended off-rate.
The slower off-rate indicated that any initial “transition state”
was less important than the formation of a stable complex dur-
ing high affinity TCR-pMHCbinding. These high affinity TCRs
enabled modification to the TCR-peptide interaction while
retaining a strong enough residual TCR-pMHC affinity to
measure using SPR. Furthermore, we were able to incorporate
mutations into individual CDR loops to generate a panel of
TCRs with an identical sequence except for their CDR2 loops.
Structural analyses confirmed that these loops were distal to
peptide binding in both wild type and enhanced affinity MEL5
and ILA1 TCRs. Based on some models of TCR engagement
(11), we reasoned that HLA A*0201-restricted TCRs with high
affinity mutations in their CDR2 loops should retain a residual
ability to bind to the surface of HLA A*0201 independently of
the peptide because the TCR-peptide interactions should only
account for a small proportion of the overall binding energy. In
contrast to this prediction,wewere unable to show binding to the
HLA A*0201-GLGGGGGGV or HLA A*0201-ALAAAAAAV
null antigens with any of the CDR2 loop high affinity TCRs
tested. These observations support the notion that specific
interactions between theTCR and peptide are required to allow
the TCR to effectively engageMHC.Using this system, wewere
also able to examine whether subtle alterations in the inter-
action between TCR and peptide were independent of TCR
CDR2 loop binding to MHC. To investigate this, we tested
the binding affinity of a panel of HLA A*0201-ILAKFLHWL-
specific CDR2 loop-modified TCRs to peptides that con-
tained alanine substitutions at positions structurally shown
to be key TCR contacts. These data revealed that even min-
imal changes to the TCR-peptide interaction had a substan-
tial impact on the TCR affinity and binding energy (G).
These data show that TCR-peptide contacts are strongly
“coupled” to TCR-MHC contacts.
We also performed a kinetic investigation of the effect of
altering the TCR-peptide interaction. These data showed that
the vastly extended off-rates that governed the enhanced affin-
ity of the high affinity mutated TCRs were effectively nullified
by altering the TCR interaction with peptide, although the on-
rates remained relatively unchanged. Thus, our data indicate
that complex formation is not initiated by TCR-MHC binding.
Rather, successful TCR-peptide sampling must precede or
occur at the same time as the stabilizing interaction between
the TCR and the MHC surface. In support of this notion, our
data show that altering the TCR interaction with peptide can
override the optimal formation of TCR-MHC interactions
resulting in a disproportionate knock-on effect on TCR-pMHC
affinity.
Mounting evidence from other studies also contests the
notion that conserved interactions between the germ line-en-
coded loops of the TCR and the MHC initiate TCR-pMHC
complex formation. First, Burrows et al. (16) have demon-
strated that disrupting conserved interactions between the
TCR andMHC surface resulted in the formation of compensa-
tory interactions. In support of these data, Dyson and co-work-
ers (49) extensively diversified CDR1 and CDR2 loops in vivo
and demonstrated that the TCR is not genetically hardwired to
engage MHC ligands. Second, a number of molecular studies
are incompatible with TCR-MHC initiated binding. These
include the following: (i) the co-crystal structure of a TCR
bound toMHCI complexed with a 13-mer “super-bulged” pep-
FIGURE 6. Schematic of the effect of alanine peptide substitutions on
TCR-pMHC binding affinity. Nonmutated TCR and pMHC components are
shown in grayscale. TCRs with high affinity mutations are shown in red. Pep-
tide mutations are shown in yellow or green. A, expected difference in the
binding of an unmodified TCR (TCR1) compared with a CDR2 loop mutated
TCR (TCR2) (mutation shown in red), assuming that the CDR2 loops bind inde-
pendently of the TCR-peptide interaction. Because the mutated CDR2 loop
(shown in red) does not contact the peptide, the theoretical difference in
binding between the TCR1 and TCR2 to peptide variants 1 (yellow) and 2
(green) compared with the wild-type peptide (black) should be identical
according the interaction between the CDR3 loops and the peptide. B, sche-
matic of the observed difference in the binding of the ILA1 11 TCR, com-
pared with the ILA1 1 TCR engaging a peptide-MHC complex. These data
show that a disproportionate knock-on effect in binding occurs for the ILA1
11 TCR, comparedwith the ILA11 TCR. Thesedata indicate that TCR-MHC
binding does not occur independently of TCR-peptide interactions and that
the latter likely governs the former.
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tide (19) showing that the extended central peptide bulge phys-
ically restricted theTCR fromcontacting theMHCsurface (Fig.
7A) (19); (ii) the co-crystal structure of a TCR bound to MHCI
complexedwith an 11-mer peptide demonstrating that the pep-
tide was “bulldozed” or flattened by the TCR, allowing the TCR
to contact the MHC surface (Fig. 7B) (20); (iii) accumulated
studies showing that TCR-MHC interactions can play a mini-
mal energetic role, compared with TCR-peptide interactions,
during TCR binding toMHC (15, 18, 21, 50), and (iv) the struc-
tures of the A6 and B7 TCRs bound to HLA A*0201-
LLFGYPVYV (27, 51, 52), showing that, despite both TCRs
sharing a genetically identical germ line-encoded V-gene
(V6-5), the TCR-MHC contacts were distinct, although a
number of identical TCR-peptide contacts existed (Fig. 7C).
Finally, our data, in which we have tested affinity-enhanced
TCRs against a range of normal tissue cell samples, show that
high affinity CDR2 mutations do not render the TCRs more
unspecific than high affinity CDR3 mutations. The examples
above are consistent with a model for T-cell antigen recogni-
tion in which TCR-peptide binding overrides TCR-MHC
engagement.
The idea that TCR-peptide contacts govern T-cell antigen
recognition is in accord with several biological requirements of
T-cell immunity. First, given that extremely weak TCR binding
is required for positive selection of peptide-dependent T-cells
in the thymus (53), control of this delicate aspect would repre-
sent a far greater challenge were TCR-MHC contacts to pro-
ceed TCR-peptide interactions (11). Second, accumulated
studies that have demonstrated that alloreactive TCR recogni-
tion is peptide-dependent (54–56) are favored bymodelswhere
TCR-peptide contacts dominate TCR engagement. Third, if
TCR-MHC interactions initiate antigen recognition then the
extraordinarily rapid kinetics ofCD8 andCD4 coreceptor bind-
ing might enable aberrant T-cell signaling, bypassing antigen-
specific TCR-peptide sampling (57). Fourth, a system where
TCR-MHC contacts dominate TCR binding is difficult to rec-
oncile with the kinetic segregation model of T-cell activation
(58, 59). In this model, small molecules such as CD2 and CD28
facilitate contact zones to enable the TCR to scan pMHCs. The
proximity of the T-cell and target cell membranes in these con-
tact zones excludes large phosphatasemolecules, such asCD45,
triggering phosphorylation of the TCR and downstream signal-
ing events. Thus, TCR-MHC binding in these contact zones
could enableTCRphosphorylation independently of TCR-pep-
tide binding. Finally, a mode of action that requires that the
TCR interacts withMHCprior to peptide scanningwastes both
time and energy. This is particularly important for a system that
requires an individual TCR to scan a multitude of pMHCmol-
ecules to locate a cognate peptide.
Wepropose two newmodels of TCR-pMHCbinding that are
accommodated by our data and are both temporally and ener-
getically complementary with a system requiring recognition of
self in the thymus and rapid intolerance of non-self in the
periphery. First, the “scan-clamp” model, in which the TCR
“scans” the peptide before “clamping” onto the MHC surface
(Fig. 8A). Second, the “synchronized docking” model, in which
there is no temporal separation between theTCRbinding to the
peptide or MHC, but TCR-peptide interactions are dominant
over TCR-MHC interactions (Fig. 8B). These new models are
consistent with the requirement for T-cells to target cells based
on their antigenic peptide, allowing them to expeditiously dis-
tinguish aberrant cells from healthy cells (60–63).
FIGURE 8.Newmodels for TCRengagementof pMHC. 1. schematic of a TCR
(dark and light gray) proceeding engagement of peptide (black)-MHC (light
gray). A, “Scan-clamp” model. Only specific TCR-peptide contacts (light gray
and black) (2A) allow the TCR (shown in dark gray) to clamp-onto the MHC
surface and (3A) complete TCR-pMHC docking, which leads to T-cell activa-
tion. B, “synchronized docking” model. TCR contacts the peptide and MHC
simultaneously (2B), but TCR-peptide interactions are dominant over TCR-
MHC interactions (3B). Only the scan clamp and synchronized docking mod-
els for T-cell antigen recognition are permissive with our data.
FIGURE 7. Structural evidence demonstrating that TCR-peptide contacts
precede TCR-MHC contacts. A, co-crystal structure of the SB27 TCR (shown
as yellow schematic) bound to the HLA-B*3508 (shown as gray yellow sche-
matic) LPEP super-bulged 13-mer peptide (shown as sticks, colored usingWil-
son “B” factor) complex. The expanded panel below illustrates the extended
conformation of the peptide, making it highly improbable that the SB27 TCR
could contact theMHC surface before the peptide (19). B, co-crystal structure
of the ELS4 TCR (shown as red yellow schematic) bound to the HLA-B*3501
(shown as gray yellow schematic) EPLP 11-mer peptide (shown as sticks, col-
ored using red complexed to the ELS4 TCR and in blue uncomplexed). The
expanded panel below illustrates how the EPLP peptide is bulldozed into a
different conformation during TCR binding (before TCR binding is shown in
blue and after TCR binding is shown in red), allowing the TCR to contact the
MHC surface (20). C, co-crystal structure of the A6 TCR (shown as green sche-
matic) superposed with the B7 TCR (shown as blue schematic) which both
bind to the HLA A*0201 (shown as gray schematic) Tax (shown as peach sche-
matic) complex (27, 51, 52). These TCRs share the same -chain germ line-
encoded CDR1 and CDR2 loops, and they bind to the sameN-terminal region
of the A2-Tax complex. The expanded panel below illustrates that the CDR3
loops engage some of the same residues of the peptide, whereas the CDR1
and CDR2 loops bind to distinct regions of the MHC surface.
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In conclusion, it is clear that T-cells have evolved to ensure
that TCR-pMHC binding is carefully balanced to guarantee
that the fidelity of antigen recognition is permissive for the
conserved and universal interactions that lead to T-cell activa-
tion. Our new data shed light on the mechanisms controlling
the seemingly paradoxical observation that a receptor-ligand
(TCR-pMHC) interaction with both a self (TCR-MHC) and
non-self (TCR-peptide) component can control T-cells by only
forming productive interactions when encountering alien
antigen.
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